EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Evaluation of Salmonella Paratyphi specific antibody quantity and function after vaccination and controlled human infection

Elizabeth Jones iD, Anna Beekmayer-Dhillon iD, Nicole Day, Tanya Dinesh, Sarthak Sahoo, Juyeon Park, Florence Mclean, Amy Flaxman, Sonu Shrestha, Eirini Pantazi, Vinay Gavade, Chandrashekhar D Kamat und 9 weitere

The Journal of Immunology · 15.04.2026 · 215 (4)

DOI: 10.1093/jimmun/vkag044 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Immunology, online erschienen am 27.04.2026. Verfasst von Elizabeth Jones und 20 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Bacterial, Salmonella paratyphi A, Paratyphoid Fever, Typhoid-Paratyphoid Vaccines. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, European Vaccine Initiative, UK Medical Research Council (MRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salmonella Paratyphi A is a major cause of paratyphoid fever. Despite growing global concern, knowledge of S. Paratyphi A immunity remains limited, and no licensed vaccine exists. In a controlled human infection model (CHIM) homologous S. Paratyphi A rechallenge showed a non-significant reduction in risk of acute disease. This study evaluates humoral immunity following experimental S. Paratyphi A exposure and vaccination with a bivalent S. Typhi–S. Paratyphi A conjugate vaccine (Sii-PTCV). Serum samples from 2 UK CHIM studies and a Phase I trial in India of Sii-PTCV were analyzed. S. Paratyphi A-specific IgG, serum bactericidal activity (SBA), antibody-dependent monocyte phagocytosis (ADMP), and neutrophil phagocytosis (ADNP) were measured pre and post-exposure or vaccination. Statistical differences were assessed using Wilcoxon matched-pairs signed rank test or the Mann–Whitney test. Experimental challenge significantly increased IgG, SBA, ADMP, and ADNP (all P < 0.0001), with strongest responses in participants who developed systemic infection. No immune marker correlated with protection in rechallenged individuals. Baseline antibody levels were higher in the Indian cohort than in the United Kingdom (P = 0.0041), suggesting prior natural exposure enhances humoral immunity. Vaccination with Sii-PTCV induced significantly greater responses than challenge, particularly for IgG (P < 0.0001), SBA (P < 0.001), and ADMP (P < 0.001). This study highlights differences in S. Paratyphi A immunity between naive and exposed populations. Both challenge and vaccination with S. Paratyphi A elicited strong humoral responses, with vaccination producing higher magnitude responses. The bivalent vaccine shows promise for paratyphoid prevention, though a clear correlate of protection remains to be defined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BacterialSalmonella paratyphi AParatyphoid FeverTyphoid-Paratyphoid VaccinesHumansImmunoglobulin GPhagocytosisMaleVaccinationNeutrophilsAdultFemaleHuman Challenge Trials as TopicImmunity, HumoralYoung AdultAdolescentMonocytes

Stichwörter der Autor:innen

Salmonella Paratyphi Afunctional immunityhumoral immunityparatyphoidvaccine response

Substanzen

Antibodies, BacterialImmunoglobulin GTyphoid-Paratyphoid Vaccines

Autor:innen und Institutionen

  • Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
  • Serum Institute of India Pvt Ltd, Pune, India.
  • Department of Infectious Disease, Imperial College London, London, United Kingdom.

ORCID-Profile: Elizabeth Jones, Anna Beekmayer-Dhillon

Förderung

  • Bill & Melinda Gates Foundation
  • European Vaccine Initiative
  • UK Medical Research Council (MRC)
  • Serum Institute India Private Limited

Zitieren

APA

Jones, E., Beekmayer-Dhillon, A., Day, N., Dinesh, T., Sahoo, S., Park, J., Mclean, F., Flaxman, A., Shrestha, S., Pantazi, E., Gavade, V., Kamat, C. D., Potey, A. V., Bharati, S., Haridasyam, V., Dhere, R. M., Pisal, S. S., Mallya, A., Kulkarni, P. S., …, & Pollard, A. J. (2026). Evaluation of Salmonella Paratyphi specific antibody quantity and function after vaccination and controlled human infection. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag044

Vancouver

Jones E, Beekmayer-Dhillon A, Day N, Dinesh T, Sahoo S, Park J, et al. Evaluation of Salmonella Paratyphi specific antibody quantity and function after vaccination and controlled human infection. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag044

BibTeX
@article{Jones2026,
  author = {Jones, Elizabeth and Beekmayer-Dhillon, Anna and Day, Nicole and Dinesh, Tanya and Sahoo, Sarthak and Park, Juyeon and Mclean, Florence and Flaxman, Amy and Shrestha, Sonu and Pantazi, Eirini and Gavade, Vinay and Kamat, Chandrashekhar D and Potey, Anirudha Vyankatesh and Bharati, Sandesh and Haridasyam, Vinodkumar and Dhere, Rajeev M and Pisal, Sambhaji S and Mallya, Asha and Kulkarni, Prasad S and Gibani, Malick M and Pollard, Andrew J},
  title = {Evaluation of Salmonella Paratyphi specific antibody quantity and function after vaccination and controlled human infection},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {4},
  doi = {10.1093/jimmun/vkag044}
}
Kostenlos starten →